Breast Cancer: CALGB 49906 (Hematology Oncology Associates)

CALGB 49906: A Phase III Study of Doxorubicin/Cyclophosphamide Therapy Followed By Paclitaxel or Docetaxel Given Weekly or Every 3 Weeks with Axillary Node-Positive or High Risk Node Negative Breast Cancer

Objective

This study involves treatment with chemotherapy to lower the risk of breast cancer returning for women that have breast cancer that has a high probability of spreading to other organs.

The purposes of this study are: 1) to compare different chemotherapy drugs in terms of side effects, survival, and disease-free survival and 2) to determine whether weekly administration of taxane chemotherapy drugs (paclitaxel and docetaxel) improves disease-free survival and overall survival when compared to the conventional (every 3 weeks) schedule.

Principal Investigator(s)
Shobha Chitneni

Clinical Trial Categories

  • Cancer
  • Breast Cancer
Sponsor(s)
Cancer and Leukemia Group B
Contact
Katy D'Aprile, RN, BSN at 563-355-7733

Location

  • Hematology Oncology Associates of the Quad Cities
    1351 East Kimberly Road
    Suite 100
    Bettendorf, IA 52722

Contact Us

For more information about our research program and IRB, please contact:

Research Support Office
563-421-7955

Email